ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: L01

Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

Yinzhu Jin 1, Hemin Lee 1, Moa Lee 2, Joan Landon 3, Joseph Merola 4, Rishi Desai 5 and Seoyoung C. Kim1, 1Brigham and Women's Hospital and Harvard Medical School, Boston, 2University of North Carolina Chapel Hill, Chapel Hill, North Carolina, 3Brigham and Women's Hospital, Boston, Massachusetts, 4Harvard Medical School, Brigham and Women's Hospital, Boston, 5Brigham and Women's hospital, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Date of first publication: October 23, 2019

Keywords: Comparative effectiveness and harms, DMARDs, Late-Breaking 2019, psoriasis, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: Late-Breaking Abstracts ePoster

Session Type: Late-Breaking Abstract Poster Session

Session Time: 9:00AM-11:00AM

Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA) patients. Limited evidence exists on the comparative risk of infection among newer medications including ustekinumab (anti-IL-12/23), secukinumab and ixekizumab (anti IL-17), and a phosphodiesterase-4 inhibitor apremilast compared with TNF inhibitors (TNFi) in patients with PsO or PsA.

Methods: We conducted a cohort study using two large US claims databases, MarketScan (9/25/2009–12/31/2017) and Optum (9/25/2009–12/31/2018). We identified the initiators of one of the following biologic DMARDS: ustekinumab, secukinumab, ixekizumab, or TNFi, (i.e., adalimumab, etanercept, infliximab, certolizumab, golimumab). Apremilast, albeit not a biologic DMARDs (bDMARDs), was also included since it is a relatively new medication used to treat PsO and PsA. The index date was the date of the 1st dispensing for a given drug. We required a 6-month washout period to define new users of each study drug. Patients were required to have at least two PsO or two PsA diagnosis during the 6-month baseline period. We excluded patients with a recent serious infection, rheumatoid arthritis, inflammatory bowel disease, malignancy, HIV, or organ transplant at baseline. Our primary outcome was a composite endpoint of hospitalized serious infection including bacterial, viral, or opportunistic infection. Follow-up time started from the day after the index date to the earliest date of the outcome, disenrollment, death, end of database, discontinuation, or switching to other study drugs. Propensity score (PS) was estimated as the predicted probability of receiving ustekinumab versus each of the aforementioned study drugs conditioning on >50 baseline characteristics. Cox proportional hazards regression estimated hazard ratios (HR) for serious infection associated with each study drug versus ustekinumab after controlling for confounding using PS-based fine stratification weights. Database-specific HRs were combined using a random-effects meta-analysis.

Results: We identified 123,383 PsO/PsA patients who initiated one of the study drugs. Among these, 61% had PsO, 22% had PsA, and 17% had both PsO and PsA. The mean (SD) age of the total cohort was 48.2 (12.8) years, and 50.6% were female (see Figure 1). The crude incidence rate per 100 person-years was highest in Infliximab (2.47 in MarketScan and 3.17 in Optum) and the lowest ixekizumab (0.69 in MarketScan) and ustekinumab (1.03 in Optum). After the PS stratification, ustekinumab had lower risk of hospitalized serious infection compared to other bDMARDs or apremilast (Figure 2). However, our estimates comparing certolizumab and golimumab versus ustekinumab were imprecise due to a limited sample size even after combining results from the two databases.

Conclusion: In this multi-database cohort of 123,383 PsO or PsA patients, ustekinumab initiators had a generally lower risk of hospitalized serious infection compared to TNFi, IL-17 therapy, and apremilast initiators.

Figure 1. Selected baseline characteristics before PS fine stratification weighting

Figure 2. Forest plots for hazard ratios of serious infection of DMARDs comparing to ustekinumab


Disclosure: Y. Jin, None; H. Lee, None; M. Lee, None; J. Landon, None; J. Merola, AbbVie, 2, 5, 8, Aclaris, 2, 5, Almirall, 2, 5, Amgen, 5, Biogen, 2, 5, Burrage Capital Management Boston Advisory Board, 6, Celgene, 2, 5, Dermavant, 2, 5, Eli Lilly, 2, 5, GSK, 2, 5, Incyte, 2, 5, Janssen, 2, 5, Leo Pharma, 2, 5, Merck Research Laboratories, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Regeneron, 5, Sanofi Regeneron, 2, 5, Sun Pharma, 2, 5, UCB, 2, 5; R. Desai, Merck, 2, Vertex, 2; S. Kim, AbbVie, 2, AstraZeneca, 2, Bristol-Myers Squibb, 2, Merck, 2, Pfizer, 2, research grants to Brigham and Women’s Hospital from Pfizer, AbbVie, Bristol-Myers Squibb, and Roche for unrelated topics, 2, Roche, 2, Roche/Genentech, 2.

To cite this abstract in AMA style:

Jin Y, Lee H, Lee M, Landon J, Merola J, Desai R, Kim S. Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/comparative-risk-of-hospitalized-serious-infection-in-patients-with-psoriasis-and-psoriatic-arthritis-a-population-based-multi-database-study/. Accessed December 10, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-risk-of-hospitalized-serious-infection-in-patients-with-psoriasis-and-psoriatic-arthritis-a-population-based-multi-database-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.